Bellicum receives fda ind clearance to initiate a phase 1/2 clinical trial for bpx-603, a dual-switch gocar-t® for her2+ solid tumors

Houston, june 15, 2020 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq:blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced clearance by the u.s. food and drug administration (fda) of its investigational new drug application (ind) for bpx-603. bpx-603 is a gocar-t® product candidate targeting solid tumors that express human epidermal growth factor receptor 2 (her2). bpx-603 is the company’s first dual-switch gocar-t® product candidate, which incorporates both the company’s imc activation and caspacide® safety switch technologies.
BLCM Ratings Summary
BLCM Quant Ranking